Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deurremidevir Hydrobromide in Infants and Young Children With RSV Infection
NCT07402512Phase 3Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing SIM0916 with SIM0916 Placebo (2 arms). Primary endpoint: Earliest time from the first dose to the sustained resolution of 6 RSV infection-related clinical signs and symptoms at Day 26. Started Mar 2026; status: recruiting.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07402512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07402512.